AAAAAA
Results: 126-150/265
Authors:
Ziade, J
Leprise, ES
Bansard, JY
Patard, JJ
Lobel, B
Guille, F
Citation: J. Ziade et al., Prostate specific antigen levels in the follow up of localised prostate cancer: how does radiotherapy compare to radical prostatectomy?, PROSTATE C, 2(3), 1999, pp. 155-158
Authors:
Shoskes, DA
Zeitlin, SI
Citation: Da. Shoskes et Si. Zeitlin, Use of prostatic massage in combination with antibiotics in the treatment of chronic prostatitis, PROSTATE C, 2(3), 1999, pp. 159-162
Authors:
Kirby, RS
Citation: Rs. Kirby, Innovators in urology, PROSTATE C, 2, 1999, pp. S1-S1
Authors:
Akakura, K
Citation: K. Akakura, The change in free-to-total prostate-specific antigen during progression to androgen-independent state in prostate cancer patients: utilization for intermittent androgen suppression therapy, PROSTATE C, 2, 1999, pp. S2-S2
Authors:
Aprikian, AG
Omar, EA
Behlouli, H
Citation: Ag. Aprikian et al., Artificial neural network analysis and the relationship of P53 and P21(waf-1) protein expression with prognosis of advanced stage prostate cancer treated by androgen ablation, PROSTATE C, 2, 1999, pp. S3-S3
Authors:
Arai, Y
Okada, T
Egawa, S
Matsumoto, K
Tobisu, K
Sagiyama, K
Sumiyoshi, Y
Hashine, K
Kawakita, M
Matsuda, T
Kakehi, Y
Terachi, T
Ogawa, O
Citation: Y. Arai et al., Radical retropubic prostatectomy: time trends, morbidity and mortality in Japan, PROSTATE C, 2, 1999, pp. S4-S4
Authors:
Bangma, CH
Kraaij, R
van Rijswijk, A
Haisma, HJ
van Beusechem, V
Gerritsen, W
Citation: Ch. Bangma et al., Transductional targeting of adenoviral vectors to prostate cancer in vitro, PROSTATE C, 2, 1999, pp. S5-S5
Authors:
Bertaccini, A
Chieco, P
Giovannini, C
Capra, I
Martorana, G
Citation: A. Bertaccini et al., Biopsying prostate gland: telomerase evaluation, PROSTATE C, 2, 1999, pp. S6-S6
Authors:
Bochner, BH
Skinner, DG
Lieskovsky, G
Citation: Bh. Bochner et al., Clinical and pathologic significance of T1c adenocarcinoma of the prostatecancer, PROSTATE C, 2, 1999, pp. S7-S7
Authors:
Brooks, JD
Paton, V
Citation: Jd. Brooks et V. Paton, Potent induction of carcinogen defence enzymes with sulforaphane, a putative prostate cancer chemopreventive agent, PROSTATE C, 2, 1999, pp. S8-S8
Authors:
Carneiro, C
da Silva, C
Citation: C. Carneiro et C. Da Silva, Phase III study on intermittent MAB vs continuous MAB: an international co-operative study, PROSTATE C, 2, 1999, pp. S9-S9
Authors:
Castro, D
Abreu, J
Alvarez-Arguelles, H
Postius, J
Flores, LD
Banares, F
Citation: D. Castro et al., Prostatic cancer: comparison of the traditional prognostic parameters, DNAanalysis results based on flow cytometry and immunohistochemical expression of protein p53, PROSTATE C, 2, 1999, pp. S10-S10
Authors:
Colombel, M
Dante, R
Bouvier, R
Ribieras, S
Pangaud, C
Marechal, JM
Lasne, Y
Citation: M. Colombel et al., Differential RNA expression of the pS2 gene in the human benign and malignant prostatic tissue, PROSTATE C, 2, 1999, pp. S11-S11
Authors:
Egawa, S
Ohori, M
Iwamura, M
Kuwao, S
Baba, S
Citation: S. Egawa et al., Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy, PROSTATE C, 2, 1999, pp. S12-S12
Authors:
Eschwege, P
Dumas, F
Benoit, G
Loric, S
Citation: P. Eschwege et al., Autologous blood transfusion as a potential source of prostate cancer cells spread during radical prostatectomy, PROSTATE C, 2, 1999, pp. S13-S13
Authors:
Evans, CP
Citation: Cp. Evans, Dual regulation of urokinase gene expression in human prostate cancer, PROSTATE C, 2, 1999, pp. S14-S14
Authors:
Gleave, M
Citation: M. Gleave, Targeting anti-apoptotic genes with antisense oligodeoxynucleotides to delay progression to androgen independence, PROSTATE C, 2, 1999, pp. S15-S15
Authors:
Hachiya, T
Minei, S
Kobayashi, K
Ishida, H
Okada, K
Citation: T. Hachiya et al., PSA nadir and risk of non-organ-confined disease in radical prostatectomy preceded by neoadjuvant androgen deprivation, PROSTATE C, 2, 1999, pp. S16-S16
Authors:
Kuczyk, M
Machtens, S
Citation: M. Kuczyk et S. Machtens, Predictive value of decreased p27 Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients, PROSTATE C, 2, 1999, pp. S17-S17
Authors:
Kyprianou, N
Citation: N. Kyprianou, Activation of TGF-beta signalling in human prostate cancer cells suppresses tumorigenicity via deregulation of cell cycle progression and induction of caspase-1 mediated apoptosis: significance in prostate tumorigenesis, PROSTATE C, 2, 1999, pp. S18-S18
Authors:
Litwin, MS
Brandeis, JM
Burnison, CM
Reiter, E
Citation: Ms. Litwin et al., Quality of life outcomes after brachytherapy for early prostate cancer, PROSTATE C, 2, 1999, pp. S19-S20
Authors:
Lokeshwar, V
Rubinowicz, D
Citation: V. Lokeshwar et D. Rubinowicz, Hyaluronic acid and hyaluronidase: molecular markers associated with prostate cancer biology and detection, PROSTATE C, 2, 1999, pp. S21-S21
Authors:
Moul, JW
Citation: Jw. Moul, Update of clinical and basic science research on prostate cancer from the department of defense center for prostate disease research (DOD-CPDR), PROSTATE C, 2, 1999, pp. S22-S22
Authors:
Muller, M
Citation: M. Muller, Determination of the enzyme telomerase in needle biopsies and fine needle aspiration cytology samples of the prostate in the diagnosis of prostate cancer, PROSTATE C, 2, 1999, pp. S23-S23
Authors:
Ogawa, O
Suzuki, T
Habuchi, T
Sasaki, R
Tachiki, Y
Akao, T
Tsuchiya, N
Kato, T
Citation: O. Ogawa et al., Association of vitamin D receptor gene polymorphism with protection against prostate cancer and benign prostate hyperplasia, PROSTATE C, 2, 1999, pp. S24-S24